VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ANGOAngioDynamics, Inc.
$12.15$505M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksANGOP/E History

ANGO logoAngioDynamics, Inc. (ANGO) P/E Ratio History

Deep Value

Trading at -14.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2005–2024

Current P/E (TTM)
-14.6x
-116% vs 5Y avg
5Y Avg P/E
93.3x
Median 58.1x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-14.6x
Min8.9xMedian58.1xMax327.1x
TTM EPS$-0.67
Price$12.15
Earnings YieldN/A
EPS Growth (1Y)81.9%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, AngioDynamics, Inc. (ANGO) trades at a price-to-earnings ratio of -14.6x, with a stock price of $12.15 and trailing twelve-month earnings per share of $-0.67.

The current P/E is 116% below its 5-year average of 93.3x. Over the past five years, ANGO's P/E has ranged from a low of 8.9x to a high of 327.1x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, ANGO trades at a 166% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, ANGO trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ANGO DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ANGO Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-14.6vs22.1
-166%
Below Sector
vs. S&P 500
-14.6vs24.4
-160%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 82% EPS growth (1Y)

ANGO P/E vs Peers

Surgical and interventional devices peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
MMSI logoMMSIMerit Medical Systems, Inc.
$4B31.6-+5%
ITGR logoITGRInteger Holdings Corporation
$3B31.57.15-15%
CNMD logoCNMDCONMED Corporation
$1B21.60.59-65%
BSX logoBSXBoston Scientific Corporation
$67B23.3-+55%
BDX logoBDXBecton, Dickinson and Company
$52B24.71.49-1%
TMDX logoTMDXTransMedics Group, Inc.
$3B16.2-+382%Best
MDT logoMDTMedtronic plc
$102B22.0-+31%
ABT logoABTAbbott Laboratories
$154B11.6Lowest0.39Best+134%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ANGO Historical P/E Data (2005–2024)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2024 Q1-$8.03$0.1650.2x-23%
FY2020 Q3Feb 29 2020$11.49$1.288.9x-86%
FY2020 Q2Nov 30 2019$15.37$1.4510.6x-84%
FY2020 Q1Aug 31 2019$18.37$1.5911.6x-82%
FY2019 Q4May 31 2019$18.79$1.6111.7x-82%
FY2019 Q3-$22.41$0.13175.9x+169%
FY2019 Q2Nov 30 2018$21.49$0.4845.0x-31%
FY2019 Q1Aug 31 2018$22.42$0.4352.5x-20%
FY2018 Q4-$21.03$0.4447.9x-27%
FY2018 Q3Feb 28 2018$16.29$0.08205.9x+215%
FY2018 Q1-$17.03$0.15114.2x+75%
FY2017 Q4May 31 2017$15.08$0.1979.4x+21%
FY2015 Q2Nov 30 2014$17.50$0.16109.8x+68%
FY2015 Q1Aug 31 2014$14.11$0.12121.0x+85%
FY2014 Q4May 31 2014$14.33$0.08169.8x+160%
FY2014 Q3Feb 28 2014$15.40$0.09170.9x+161%
FY2012 Q3Feb 29 2012$13.02$0.04327.1x+400%
FY2012 Q2Nov 30 2011$15.12$0.2658.1x-11%
FY2012 Q1Aug 31 2011$14.40$0.3048.0x-27%
FY2011 Q4-$15.70$0.3347.5x-27%
FY2011 Q3Feb 28 2011$16.82$0.5133.0x-50%
FY2011 Q2-$13.97$0.4928.5x-56%
FY2011 Q1-$15.22$0.4931.1x-52%
FY2010 Q4May 31 2010$14.77$0.5029.5x-55%
FY2010 Q3Feb 28 2010$16.26$0.4734.6x-47%
FY2010 Q2Nov 30 2009$15.55$0.4237.0x-43%
FY2010 Q1Aug 31 2009$12.95$0.4131.6x-52%
FY2009 Q4May 31 2009$12.30$0.4130.0x-54%
FY2009 Q3Feb 28 2009$11.87$0.3138.2x-42%
FY2009 Q2Nov 30 2008$11.93$0.4327.7x-58%
FY2009 Q1Aug 31 2008$16.43$0.4437.3x-43%
FY2008 Q4May 31 2008$15.49$0.4534.3x-47%
FY2008 Q3Feb 29 2008$16.58$0.5530.1x-54%
FY2007 Q2Dec 02 2006$21.18$0.5439.2x-40%
FY2007 Q1Sep 02 2006$18.09$0.5234.8x-47%
FY2006 Q4May 31 2006$28.00$0.5056.0x-14%
FY2006 Q3Feb 25 2006$25.31$0.5050.6x-23%
FY2006 Q2Nov 26 2005$20.07$0.4544.6x-32%
FY2006 Q1Aug 27 2005$22.17$0.4154.1x-17%
FY2005 Q4-$19.77$0.3753.4x-18%
FY2005 Q3Feb 26 2005$21.73$0.3758.7x-10%

Average P/E for displayed period: 65.4x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

21+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ANGO — Frequently Asked Questions

Quick answers to the most common questions about buying ANGO stock.

What is ANGO's P/E ratio?

AngioDynamics, Inc. (ANGO) trailing twelve-month P/E ratio is -14.6x, based on TTM diluted EPS of $-0.67. The 5-year average P/E is 93.3x and the historical range spans 8.9x to 327.1x.

Is ANGO stock overvalued or undervalued?

ANGO trades at -14.6x P/E, below its 5-year average of 93.3x. At the 0th percentile of its historical range (8.9x–327.1x), the stock is priced at a discount to its own history.

Is ANGO stock expensive?

No, ANGO is not expensive on a historical basis. The current P/E of -14.6x is below the 5-year average of 93.3x and sits at the 0th percentile of its valuation range.

What is ANGO's historical P/E range?

Over the past 5 years, ANGO's P/E ratio has ranged from 8.9x to 327.1x, with a median of 58.1x and an average of 93.3x. The current P/E of -14.6x places the stock at the 0th percentile of this range. Full historical data spans 2005–2024.

How does ANGO's P/E compare to the S&P 500?

ANGO trades at -14.6x P/E versus the S&P 500 median of 24.4x. The 160% discount to the market suggests lower growth expectations or perceived higher risk.

How does ANGO's valuation compare to Healthcare peers?

AngioDynamics, Inc. P/E of -14.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ANGO's PEG ratio?

ANGO PEG ratio is N/A, based on a P/E of -14.6x and EPS growth of 81.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ANGO's earnings yield?

ANGO earnings yield is N/A, the inverse of its -14.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ANGO P/E Ratio History (2005–2024)

Quarterly valuation multiple from closing price and trailing EPS

Current50.2x
Period Avg93.3x
Range8.9x - 327.1x
Change+6%
20 quartersMay 31, 2011 - Aug 31, 2023